Established biomarker predicts HF in type 2 diabetes
medwireNews: When levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) are persistently high or rising, patients with type 2 diabetes are at increased risk for being hospitalized with heart failure (HF) or dying of cardiovascular causes, research shows.
The study of 4282 participants of the EXAMINE trial showed that the rate of HF hospitalization over 2 years was just under 10% for those with high NT-proBNP levels (≥400 pg/mL) at both baseline and 6 months and over 5% for those whose levels changed from low (<400 pg/mL) to high in that time. By contrast, HF occurred in 1% or less of patients whose levels remained low or fell from high to low.
The same was true for the combined outcome of HF hospitalization or cardiovascular death, with corresponding levels of around 20%, 10% and less than 5%, report Petr Jarolim (Brigham and Women’s Hospital, Boston, Massachusetts, USA) and co-researchers.
The findings support the use of “natriuretic peptides for serial monitoring of patients with diabetes and ischemic heart disease whose diseases are in a seemingly clinically stable phase,” they write in Diabetes Care.
All patients in EXAMINE had an acute coronary syndrome event within 15–90 days before enrollment. Being randomized to receive alogliptin did not significantly influence their NT-proBNP levels.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group